VIP
VIP10 (10mg)
$190USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.281
Reference number
10mg
Lyophilized vial
Vasoactive Intestinal Peptide fragment. Neuropeptide studied for vasodilatory, anti-inflammatory, and immunomodulatory effects.
Origin
Vasoactive Intestinal Peptide (VIP) was first isolated from porcine duodenum by Said and Mutt in 1970 at the Karolinska Institute in Stockholm. Originally identified for its potent vasodilatory properties, it was subsequently found to be widely distributed throughout the central and peripheral nervous systems as a neurotransmitter and neuromodulator.
Research Lineage
Said's original work was followed by extensive characterization by Gozes, Brenneman, and colleagues demonstrating neuroprotective properties. Delgado and Ganea established VIP's immunomodulatory role. Langer et al. investigated its pulmonary distribution. Over 10,000 PubMed entries reference VIP, spanning neuroscience, immunology, and respiratory physiology.
Mechanism of Action
VIP signals through two G-protein coupled receptors: VPAC1 and VPAC2. Receptor activation stimulates adenylyl cyclase, increasing intracellular cAMP. This mediates smooth muscle relaxation (vasodilation, bronchodilation), stimulates secretion in intestinal and respiratory epithelia, and inhibits pro-inflammatory cytokine production by immune cells. In the CNS, VIP acts as a neurotrophic factor and circadian rhythm regulator in the suprachiasmatic nucleus.
Structural Notes
28-amino-acid neuropeptide (full-length VIP). VIP10 refers to a 10-amino-acid fragment. Member of the secretin/glucagon peptide superfamily. Molecular weight (full): 3326.8 Da.
Key References
Said SI, Mutt V. Science. 1970;169(3951):1217-8.
Delgado M, Ganea D. Brain Behav Immun. 2008;22(1):35-46.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.